These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23639510)

  • 1. In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.
    Chen SH; Kuo YT; Cheng TL; Chen CY; Chiu YY; Lai JJ; Chang CC; Jaw TS; Wang YM; Liu GC
    Kaohsiung J Med Sci; 2013 May; 29(5):246-53. PubMed ID: 23639510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new biodegradable and biocompatible gadolinium (III) -polymer for liver magnetic resonance imaging contrast agent.
    Xiao Y; Xue R; You T; Li X; Pei F
    Magn Reson Imaging; 2015 Jul; 33(6):822-8. PubMed ID: 25839395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
    Erstad DJ; Ramsay IA; Jordan VC; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM
    Invest Radiol; 2019 Nov; 54(11):697-703. PubMed ID: 31356382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Gd(III)-based receptor-induced magnetization enhancement (RIME) contrast agent for β-glucuronidase activity profiling.
    Chen SH; Kuo YT; Singh G; Cheng TL; Su YZ; Wang TP; Chiu YY; Lai JJ; Chang CC; Jaw TS; Tzou SC; Liu GC; Wang YM
    Inorg Chem; 2012 Nov; 51(22):12426-35. PubMed ID: 23116118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a Gadolinium-Based Nanoparticle (AGuIX) for Contrast-Enhanced MRI of the Liver in a Rat Model of Hepatic Colorectal Cancer Metastases at 9.4 Tesla.
    Fries P; Morr D; Müller A; Lux F; Tillement O; Massmann A; Seidel R; Schäfer T; Menger MD; Schneider G; Bücker A
    Rofo; 2015 Dec; 187(12):1108-15. PubMed ID: 26361379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
    Chong HS; Garmestani K; Bryant LH; Milenic DE; Overstreet T; Birch N; Le T; Brady ED; Brechbiel MW
    J Med Chem; 2006 Mar; 49(6):2055-62. PubMed ID: 16539394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats.
    Mandry D; Pedersen M; Odille F; Robert P; Corot C; Felblinger J; Grenier N; Claudon M
    Invest Radiol; 2005 May; 40(5):295-305. PubMed ID: 15829826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid conjugate of arabinogalactan as a potential liver-targeting magnetic resonance imaging contrast agent.
    Xiao Y; Xue R; You T; Li X; Pei F; Wang X; Lei H
    Carbohydr Res; 2014 Aug; 395():9-14. PubMed ID: 24995911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new gadolinium-based contrast agent for magnetic resonance imaging of brain tumors: kinetic study on a C6 rat glioma model.
    Fonchy E; Lahrech H; François-Joubert A; Dupeyre R; Benderbous S; Corot C; Farion R; Rubin C; Décorps M; Rémy C
    J Magn Reson Imaging; 2001 Aug; 14(2):97-105. PubMed ID: 11477666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and performance of biocompatible gadolinium polymer as liver-targeting magnetic resonance imaging contrast agent.
    Hu T; Wan C; Zhan Y; Li X; Zheng Y
    J Biosci Bioeng; 2024 Feb; 137(2):134-140. PubMed ID: 38195341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64).
    Kobayashi H; Saga T; Kawamoto S; Sato N; Hiraga A; Ishimori T; Konishi J; Togashi K; Brechbiel MW
    Cancer Res; 2001 Jul; 61(13):4966-70. PubMed ID: 11431325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biodistribution study of self-assembled Gd-micelles demonstrating blood-pool contrast enhancement for MRI.
    Vorobiev V; Babič A; Crowe LA; Van De Looij Y; Lenglet S; Thomas A; Helm L; Vallée JP; Allémann E
    Int J Pharm; 2019 Sep; 568():118496. PubMed ID: 31279053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and characterization of a new bioactivated paramagnetic gadolinium(III) complex [Gd(DOTA-FPG)(H2O)] for tracing gene expression.
    Chang YT; Cheng CM; Su YZ; Lee WT; Hsu JS; Liu GC; Cheng TL; Wang YM
    Bioconjug Chem; 2007; 18(6):1716-27. PubMed ID: 17935289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of [Gd(Bz-TTDA)]2- as a potential contrast agent in MR imaging of the hepatobiliary system: an animal study.
    Hsu JS; Jaw TS; Liu GC; Wang YM; Chen SH; Kuo YT; Jao JC; Li CW; Tsai KB
    J Magn Reson Imaging; 2004 Oct; 20(4):632-9. PubMed ID: 15390149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gd-complexes of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-1,4,7,10-tetraacetic acid (DOTA) conjugates of tranexamates as a new class of blood-pool magnetic resonance imaging contrast agents.
    Gu S; Kim HK; Lee GH; Kang BS; Chang Y; Kim TJ
    J Med Chem; 2011 Jan; 54(1):143-52. PubMed ID: 21141934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved tumor-targeting MRI contrast agents: Gd(DOTA) conjugates of a cycloalkane-based RGD peptide.
    Park JA; Lee YJ; Ko IO; Kim TJ; Chang Y; Lim SM; Kim KM; Kim JY
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):246-50. PubMed ID: 25449282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
    Chandrasekharan P; Yong CX; Poh Z; He T; He Z; Liu S; Robins EG; Chuang KH; Yang CT
    Biomaterials; 2012 Dec; 33(36):9225-31. PubMed ID: 23026708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.